The handling of Hazardous medical drugs in a cancer treatment unit requires a specific approach in order to avoid unnecessary risks for the healthcare staff, and more particularly for the nurses. The measures to be taken concern both the preparation and administration phases.
BOARD’S POSITION PAPERS
CytoPrevent* Advisory Board proposals to update the CMD.
While the European Commission has just started the Trilog process to amend the Carcinogen and Mutagen Directive (CMD) , CytoPrevent Advisory Board wishes to express some key concerns and formulates its expectations regarding the outcomes.
The need to use a more appropriate acronym for CSTDs for administration of cytotoxic drugs.
Proposal for including in the amendment of Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work, a specific name for closed system used for administration of chemotherapy.
The CytoPrevent board strongly supports the European Parliament vote to include hazardous drugs and reprotoxics in the Carcinogens and Mutagens Directive (CMD) to guaranty a safer working environment for healthcare professionals.
Dear Madam, Sir, CytoPrevent, a group of scientific experts, would like to use the opportunity to give our comments and suggestions on “work involving exposure to cytostatic agents”. We appreciate the appraisal as a step forward to improve worker’s safety and health...